GET DAILY SIGNALSNeurocrine Biosciences (NBIX) Delivers +41% Revenue Growth in Strong Q3 Report
Key Takeaways
- Total revenues climbed 41% year over year to $1.12 billion, while net product sales surpassed $1 billion in a single quarter for the first time.
- Non-GAAP diluted earnings per share (EPS, a profitability measure that excludes certain one-time or non-cash items) came in at $3.29, far above the roughly $1.91 consensus estimate.
- GAAP diluted EPS was $1.96, down 4% from $2.04 a year earlier, reflecting acquisition-related charges and an equity-investment loss.
- INGREZZA net product sales rose 17% to $801 million, and the company raised its full-year 2026 sales guidance for the drug.
- Newer products CRENESSITY and VYKAT XR delivered strong growth, with CRENESSITY sales up 115% year over year.
- Shares rose roughly 6.9% in after-hours trading following the report.
Why These Results Stand Out
Neurocrine Biosciences has spent 2026 shifting from a company centered on its flagship movement-disorder treatment, INGREZZA, toward a broader multi-product biopharmaceutical operation. The acquisition of Soleno Therapeutics brought in VYKAT XR for hyperphagia in Prader-Willi syndrome, while CRENESSITY continues to expand in congenital adrenal hyperplasia. This quarter offered a clear check on whether that expanded portfolio can maintain momentum even as the firm invests in a late-stage pipeline that includes programs for major depressive disorder and schizophrenia. Surpassing $1 billion in quarterly product sales represents a notable step forward and supports confidence in the longer-term growth path.
Quarterly Performance Breakdown
For the third quarter ended September 30, 2026, Neurocrine Biosciences posted total revenues of $1.12 billion, a 41% increase from $794.9 million in the same period last year and ahead of the roughly $1.04 billion consensus estimate. Net product sales reached $1.12 billion. Non-GAAP diluted EPS reached $3.29, up 52% from $2.17 a year earlier and well above the approximately $1.91 analysts had projected. On a GAAP basis, diluted EPS was $1.96, compared with $2.04 in the prior-year quarter. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
At the product level, results showed solid breadth. INGREZZA net product sales increased 17% to $801 million, helped by record total and new prescriptions. CRENESSITY net product sales jumped 115% to $211 million, with about 80% reimbursement on dispensed prescriptions. VYKAT XR added $107 million in its second full quarter under Neurocrine’s ownership. Management lifted full-year 2026 INGREZZA sales guidance to a range of $2.90 billion to $2.925 billion, up from $2.825 billion to $2.875 billion previously, and also trimmed its GAAP and Non-GAAP selling, general, and administrative expense guidance.
Market Response and Investor View
The market reacted positively to the results, with Neurocrine shares climbing roughly 6.9% in after-hours trading to around $155. The size of the Non-GAAP EPS beat, along with the raised INGREZZA guidance, helped ease concerns following a stretch of relative weakness that had left the stock down about 9% over the prior three months. The continued CRENESSITY momentum and early contribution from VYKAT XR reinforced the sense that the company is successfully broadening its base beyond the lead product, even as GAAP profitability faced pressure from acquisition-related amortization and an unrealized loss on equity investments.
What Comes Next
Going forward, attention will focus on whether the company can keep double-digit prescription growth across INGREZZA, CRENESSITY, and VYKAT XR while completing the integration of the Soleno acquisition. Management noted that VYKAT XR growth could face some near-term delays as it addresses real-world safety communications, though it remains confident in the product’s benefit-risk profile and plans additional studies starting in 2027.
The pipeline stays a key area of focus. Neurocrine has begun a Phase 1 study of NBIP-1968, an investigational triple agonist for obesity, along with the Phase 1 CRF2 agonist NBIP-2118, with early data expected to inform a potential combination strategy. A Phase 2 study of NBI-567, a selective muscarinic agonist for cognition in Alzheimer’s disease, is also underway.
Near-term catalysts include Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia, both anticipated in 2027, plus the company’s R&D Day set for December 15, 2026. Investors will continue to track cost trends, as research and development spending keeps rising to support the growing clinical portfolio.
Using AI Tools in My Research
I often turn to Tickeron’s AI Screener when analyzing earnings reports like this one. It helps me quickly filter for comparable names in the sector and spot technical patterns or performance trends that might otherwise take hours to review manually. The tool has become a regular part of how I cross-check company results against broader market signals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NBIX in +2.31% Uptrend, rising for three consecutive days on October 27, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NBIX advanced for three days, in 222 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NBIX's RSI Indicator exited the oversold zone, 19 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on NBIX as a result. In 61 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for NBIX just turned positive on October 20, 2026. Looking at past instances where NBIX's MACD turned positive, the stock continued to rise in 33 of 53 cases over the following month. The odds of a continued upward trend are 62%.
NBIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for NBIX moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
The Aroon Indicator for NBIX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 58 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.000) is normal, around the industry mean (8.329). P/E Ratio (20.617) is within average values for comparable stocks, (-1.568). Projected Growth (PEG Ratio) (0.280) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (4.587) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a product based biopharmaceutical company
Industry PharmaceuticalsGeneric